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Accepted 4 September 2013The beginning of the 21st century has been a time of
change in stem cell transplantation (SCT) practice, particu-
larly in terms of donor selection for pediatric patients. We
have witnessed a decline in peripheral blood SCT (PBSCT) in
favor of bone marrow (BM) as a donor source, leading to less
graft-versus-host disease (GVHD) [1]. With the acquisition of
a critical pool of more than 12 million unrelated donors
worldwide, this adult stem cell source has achieved some
stability in terms of donor availability [2]. However, umbilical
cord blood transplantation (CBT) has seen growing accep-
tance as a ready stem cell source with a low risk for GVHD
even with donorerecipient mismatch. The perfection of CBT
selection criteria alongwith concurrent improvements in the
quality of cord blood products has produced continuing
improvements in transplantation outcomes [3]. Successful
new transplantation approaches with related haploidentical
SCT promise to again reset the criteria for donor source
selection [4]. The article by Oshrine et al [5] in this issue of
The Journal opens up a further strategy, using partially
T celledepleted (TCD) PBSCT as an alternative to CBT, espe-
cially in mismatched SCT.
The study objectives of Oshrine et al’s Children’s Hospital
of Philadelphia group derive from 2 competing problems
facing mismatched allogeneic SCT: immune recovery and
GVHD. Compared with CBT, PBSCT can transfer immunity to
viruses (especially cytomegalovirus) from a seropositive
donor, whereas CBT, with only virus-naïve T cells, confers
a greater risk of uncontrolled viral reactivation and disease
[3]. However, compared with CBT, unmanipulated PBSCT
carries an unacceptably high risk of GVHD [1]. These obser-
vations set the stage for exploring the option of TCD PBSCT.
There is good reason to presume that TCD PBSCT can reduce
the risk of GVHD to even below that of unmanipulated BM
transplantation, but the ability of TCD PBSCT to establish
immune function requires further investigation [6].
In fact, Oshrine et al’s study, which compared 55 TCD
PBSCTs and 21 CBTs, showed distinct differences in theFinancial disclosure: See Acknowledgments on page 1532.
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CD8 T cell recovery was comparable, CD4 recovery was much
slower after TCD PBSCT, andwas complete only after a second
wave of lymphocyte recovery associated with recovering
thymopoiesis. Because the anti-CD20 monoclonal antibody
rituximab was used in the PBSCTs to prevent Epstein-Barr
virus (EBV) lymphoproliferative disease, the recovery of
CD19þ B cells was also slower. (The use of rituximab could be
considered overkill, given that EBV reactivation has not been
reported as a signiﬁcant problem in TCD PBSCT, and that
rituximab carries its own risk of delayed neutropenia [7].)
Despite these strategies, the 2 groups demonstrated no
difference in T cell mitogen responses or in the need for
i.v. immunoglobulin. Most notably, outcomes were highly
comparable in the 2 groups, with similar rates of relapse,
transplantation-related mortality, and overall survival.
However, there was less chronic GVHD with PBSCT, although
the difference were not statistically signiﬁcant. Oshrine et al
conclude that partial TCD PBSCT offers a useful alternative to
unrelated CBT in pediatric patients. They suggest that a TCR-
a/bepositive T cell depletion strategy, currently under eval-
uation in Europe, could further improve immune recovery by
sparing natural killer cells and other accessory cells that are
eliminated with the CD34þ selection method [8].
Given the small group size and nonrandomized nature of
the study of Oshrine et al, their ﬁndings should not be
regarded as deﬁnitive evidence of the superiority or even
equivalence of TCD PBSCT compared with CBT. Nonetheless,
their study can be considered a hypothesis-generating study
supporting a larger randomized trial comparing CBT with
TCD PBSCT. Two issues need to be addressed: the risk of
GVHD and the optimum stem cell dose. In terms of GVHD, in
the context of partially matched donors, CBT permits greater
latitude of mismatch with a lower risk of acute and chronic
GVHD compared with unmanipulated BM transplantation or
PBSCT; however, more data are needed for TCD PBSCT. In
terms of stem cell dose, the lower CD34 cell dose and slower
engraftment in CBT are problems that have not yet been
entirely overcome by the use of double cord or haploidentical
cord transplants or stem cell expansion [9,10]. In contrast,
PBSCT uses the optimum stem cell source, with supermassive
CD34 cell doses (>106/kg) regularly achievable, especially in
the pediatric population. Over and above overcoming the
slow engraftment characteristic of unrelated CBT, such
megadoses of CD34 cells should reduce graft rejection,
especially in the mismatched setting. Whether such TCD
transplants would still retain sufﬁcient numbers of T cells to
restore immunity and protect against viral reactivation
remains an important unanswered question.
P.L. McCarthy / Biol Blood Marrow Transplant 19 (2013) 1531e15331532Although transplantation teams have been very successful
in managing the characteristically slow hematologic recovery
after CBT, a large comparative study of CBT versus TCD PBSCT
might well reveal a signiﬁcant outcome beneﬁt for the richer
stem cell product. Together with the intrinsic opportunities
conferred by PBSCT of a continuing source of lymphocytes
and stem cells to treat disease relapse and BM failure, such
a study could swing the balance away from CBT in favor of
TCD PBSCT. We live in a time of rapid advances, however; by
the time such a clinical trial is conceived and implemented,
related haploidentical SCT may emerge as a key contender to
be evaluated against unrelated donor SCT [4].
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poietic stem cell transplantation (auto-HSCT) remains an
integral component of the treatment of transplantation-
eligible patients with multiple myeloma (MM). This treat-
ment is technically not a transplantation, but rather is
a rescue from the marrow-toxic effects of melphalan using
the patient’s own hematopoietic stem cells (HSCs); however,
the term “transplantation” is widely used to describe this
treatment, and so is used herein.
Melphalan has been dose-intensiﬁed to treat plasma cell
leukemia and MM [1], but this therapy is limited by pro-
longed pancytopenia at higher doses of melphalan. Barlogie
et al. [2] initially demonstrated the utility of auto-HSCT with
bone marrow (BM) grafts, leading to the broad application
of auto-HSCT as part of the continuum of initial or later
treatment of transplantation-eligible patients with MM. The
ﬁrst use of mobilized peripheral blood (PB) as a stem cell
source was reported in 1989 [3] and has led to the use of
growth factor (with or without chemotherapy)emobilized
PB as a stem cell source, usually after a high-dosemelphalan-based regimen. A phase III study demon-
strating the superiority of auto-HSCT over chemotherapy
had led to the widespread use of auto-HSCT as part of the
initial therapy for transplantation-eligible patients with MM
[4]. Terms for the autologous HSCs used for rescue/trans-
plantation include BM, blood or marrow (allowing for the
continued use of BM as an abbreviation), PB, HSCs, and
hematopoietic progenitor cells (HPCs).
The study of Costa et al. [5] reported in this issue of
Biology of Blood and Marrow Transplantation demonstrates
the increased use of auto-HSCT as part of the initial therapy
for transplantation-eligible patients with MM from 1995 to
2010. The study population comprised 20278 patients with
MM, 11644 of whom underwent auto-HSCT between 2005
and 2010. Given the formidable challenge of collecting
complete data from more than 20000 patients, the investi-
gators conducted a detailed analysis of a subset of 4373
patients with more detailed information. This study further
limited eligibility to patients who were within 1 year of MM
diagnosis, thus reﬂecting early and possibly more aggressive
disease. This eligibility criterion did not capture those
smoldering patients with MM requiring therapy more than 1
year after the initial diagnosis. The cohort likely reﬂects the
majority of symptomatic transplantation-eligible patients
withMM, but this is uncertain, owing to the large percentage
of patients without Durie-Salmon and International Staging
System scores at diagnosis (49% and 39%, respectively).
Factors that have changed over time include the increasing
use of auto-HSCT in patients aged 65 years, the abandon-
ment of most nonemelphalan-containing regimens in favor
of single-agent melphalan regimens, the increased use of
planned tandem auto-HSCT, and the increased use of
